Complement Activation: The role in Health and Disease and Strategies of Therapeutic Complement Inhibition

作者: Nayareen Akhtar , Rezwanur Rahman , Shahin Sultana , Nurun Nahar Mawla

DOI: 10.12691/AJMSM-2-6-1

关键词: Tissue homeostasisAlternative complement pathwayClassical complement pathwayBiologyComplement systemImmunologyAnaphylatoxinComplement receptorImmune systemComplement (complexity)

摘要: The multiple interconnections among complement proteins, immune cells, and mediators provide an excellent mechanism to protect the organism against infections support repair of damaged tissues. However, disturbances in this "defense machinery" contribute pathogenesis various diseases. role inflammatory disorders is multifaceted; for example, activation can significantly inflammation-mediated tissue damage, whereas inherited or acquired deficiencies highly favor development autoimmunity. Complement as essential component system substantial relevance destruction invading microorganisms maintaining homeostasis including protection autoimmune involvement a great number partly life threatening diseases defines importance develop inhibitors which specifically interfere with its deleterious action. Endogenous soluble complement-inhibitors, antibodies low molecular weight antagonists, either blocking key proteins cascade reaction neutralizing action complement- derived anaphylatoxins have successfully been tested animal models over past years.

参考文章(84)
R Skibbens, H C Marsh, L Berman, C G Yeh, S M Scesney, K A Donahue, R E Kuestner, M F Concino, S H Ip, G R Carson, Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats. Journal of Immunology. ,vol. 146, pp. 250- 256 ,(1991)
S J Piddlesden, H Lassmann, B P Morgan, A M Freeman, M K Storch, M Hibbs, Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. Journal of Immunology. ,vol. 152, pp. 5477- 5484 ,(1994)
H B Hechtman, F D Moore, J Hill, F Ortiz, C G Yeh, T F Lindsay, Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. Journal of Immunology. ,vol. 149, pp. 1723- 1728 ,(1992)
M S Mulligan, D C Anderson, A R Rudolph, J S Warren, C W Smith, C G Yeh, P A Ward, Lung injury after deposition of IgA immune complexes. Requirements for CD18 and L-arginine. Journal of Immunology. ,vol. 148, pp. 3086- 3092 ,(1992)
Joshua M. Thurman, V. Michael Holers, The Central Role of the Alternative Complement Pathway in Human Disease The Journal of Immunology. ,vol. 176, pp. 1305- 1310 ,(2006) , 10.4049/JIMMUNOL.176.3.1305
A Gorrell, H Fuchs, E Martin, P Moran, H Beasley, P Gribling, I W Caras, N Gillett, L E Burton, Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. Journal of Immunology. ,vol. 149, pp. 1736- 1743 ,(1992)
M Pemberton, G D Ross, D E Justus, V Vĕtvicka, G Anderson, Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. Journal of Immunology. ,vol. 150, pp. 5104- 5113 ,(1993)
Boris J. Czermak, Vidya Sarma, Carl L. Pierson, Roscoe L. Warner, Markus Huber-Lang, Nicolas M. Bless, Hagen Schmal, Hans Peter Friedl, Peter A. Ward, Protective effects of C5a blockade in sepsis Nature Medicine. ,vol. 5, pp. 788- 792 ,(1999) , 10.1038/10512
D. E. Griswold, J. Vernick, C. G. Yeh, R. Rabinovici, K. L. L. Fong, G. Feuerstein, M. J. Dimartino, L. M. Hillegass, Role of complement in endotoxin/platelet-activating factor-induced lung injury. Journal of Immunology. ,vol. 149, pp. 1744- 1750 ,(1992)
B. R. Thorley, D. Christiansen, J. Milland, B. E. Loveland, P. L. Mottram, L. J. Purcell, I. F. C. Mckenzie, Engineering of recombinant soluble CD46: an inhibitor of complement activation. Immunology. ,vol. 87, pp. 348- 354 ,(1996)